Our team is made up of cancer drug development professionals with years of experience and expertise in the life sciences industry. Together with our academic collaborators and advisors, we share a common dedication to world-class research aimed at commercializing new therapies that improve survival outcomes and quality of life for cancer patients.
Dr. Brown has been involved in cancer drug discovery and development for more than 35 years. Initially at Stanford University in collaboration with SRI International where he was involved in drug-screening activities sponsored by the U.S. National Cancer Institute. Dr. Brown has founded or co-founded multiple companies including Matrix Pharmaceutical, Inc. (acquired by Chiron Corp. in 2002), ChemGenex Pharmaceuticals (acquired by Cephalon/Teva in 2011) and Kintara Therapeutics, Inc. (NASDAQ: KTRA, formerly DelMar Pharmaceuticals, Inc.).
During his career, Dr. Brown has been involved in the discovery and development of multiple FDA-approved cancer therapies. He currently serves as a member of the National Brain Tumor Society Research Roundtable, as a consultant to DelMar Pharmaceuticals, as Chairman of Mountain View Pharmaceutical’s Board of Directors and is the President of Valent Technologies LLC, which has been involved in the discovery of Edison Oncology’s drug candidates.
He also previously served as an Assistant Professor of Radiology at Harvard University Medical School and as a Research Associate in Radiology at Stanford University Medical School. He received his B.A. in Biology and Chemistry (1971), M.S. in Cell Biology (1975) and Ph.D. in Radiation and Cancer Biology (1979), all from New York University. Dr. Brown is an inventor of more than 40 issued U.S. patents and applications, many with foreign counterparts.
Mr. Bacha has been involved in pharmaceutical research and corporate development for more than 25 years as a member of the executive leadership team for multiple companies.
Mr. Bacha co-founded DelMar Pharmaceuticals (now, Kintara Therapeutics, Inc. NASDAQ: KTRA) with Dr. Dennis Brown and served as Chairman and CEO during the company’s growth including the advancement of its lead product candidate to pivotal Phase III clinical trials and NASDAQ listing.
Prior to founding DelMar, Mr. Bacha served as president and founding CFO of XBiotech, Inc. (NASDAQ: XBIT), founding CEO of Inimex Pharmaceuticals and Vice President, Corporate Development at Inflazyme Corp. Programs advanced by Inimex and Inflazyme have become foundational in Soligenix, Inc. (NASDAQ: SNGX) and Aquinox Pharmaceuticals (NASDAQ: AQXP).
He is a member of the National Brain Tumor Society Research Roundtable and the Board of the Leukemia Lymphoma Society of Canada. Mr. Bacha currently serves as a consultant to Valent Technologies LLC, and as a member of the Board of Directors of Sernova Corp. (TSX-V: SVA). Prior to taking on his operating roles, Mr. Bacha served Senior Manager and Director of KPMG Health Ventures, acting as an advisor to numerous public and private life sciences companies.
Mr. Bacha holds an M.B.A (Hons) from the Goizueta Business School at Emory University (1995) and a degree in BioPhysics from the University of California, San Diego (1991). Mr. Bacha is the inventor or co-inventor on multiple issued U.S. patents and applications, many with foreign counterparts.
John K. Bell serves as lead independent director and chair of the audit committee.
Mr. Bell is the founder of Shred-Tech Ltd. and Polymer Technologies, Inc., John K. Bell is a businessperson who has been the head of 15 different companies and presently is Chairman at CrossChasm Technologies, Inc., Chairman & Chief Executive Officer at Onbelay Investment Corp., Chairman for Stack Capital Group, Inc., lead independent director of Edison Oncology Holding Corp., and Director & Governor at Stratford Festival. He is also on the board of Stratford Shakespearean Festival of America.
Mr. Bell was a founding investor of Research in Motion (Blackberry) and previously held the position of Director at Canopy Growth Corp. and Chairman of Canopy Rivers Corp. (a subsidiary of Canopy Growth Corp.), Chairman of Waterloo Regional Police Service, Chairman of Prosperity Council of Waterloo Region, Director at RIV Capital, Inc., Chief Executive Officer & Director at ATS Corp., Chief Executive Officer & Owner at Shred-Tech Ltd., Director at BSM Technologies, Inc., Director at BSM Technologies Ltd., Chairman of HEXO Corp., President & Chief Executive Officer of Polymer Technologies, Inc., Chairman of Cambridge Memorial Hospital, Member of Institute of Corporate Directors and Secretary & Director at Crohn’s & Colitis Foundation of Canada.
John K. Bell received an undergraduate degree from Richard Ivey School of Business.
